Experimental preclinical models that resemble patient tumors can improve target identification and therapeutic efficacy. Patient-derived xenograft (PDX) models, due to their genomic and transcriptomic similarity to patient tumors, can improve preclinical testing of drug combinations. Despite previous development of breast PDX models, models derived from patients with triple negative breast cancer are lacking. One study applied hybrid imaging analysis to a PDX model of triple negative breast cancer to validate the method for use in clinical practice based on evaluated and validated mouse models. Limited utility of established tumor cell lines has made transplantable tumor xenograft models superior for refining preclinical models with new knowledge of tumor heterogeneity. A study analyzed gene expression in 93 cases of triple negative breast cancer